瑞舒伐他汀联合依折麦布治疗糖尿病肾病临床观察

Clinical Observation on Rosuvastatin Combined with Ezetimibe in the Treatment of Diabetic Nephropathy

目的探讨瑞舒伐他汀联合依折麦布治疗糖尿病肾病的临床疗效及对患者尿白蛋白排泄率(UAER)、血管细胞黏附分子1(VCAM-1)、Ⅳ型胶原(CⅣ)及Ⅲ型前胶原(PCⅢ)的影响。方法选取医院2016年6月至2017年6月收治的糖尿病肾病患者70例,按治疗方案的不同分为试验组和对照组,各35例。对照组予瑞舒伐他汀钙片20 mg,口服,每天1次;试验组予瑞舒伐他汀钙片10 mg及依折麦布片10 mg,口服,均每天1次。两组均连续治疗12周。结果与治疗前比较,两组患者空腹血糖(FBG)、血肌酐(SCr)、平均动脉压(MAP)、血尿素氮(BUN)及UAER,VCAM-1,CⅣ,PCⅢ水平均显著降低,且试验组上述指标改善程度均显著优于对照组(P<0.05)。结论瑞舒伐他汀联合依折麦布治疗糖尿病肾病可降低UAER,VCAM-1,CⅣ,PCⅢ水平,并改善血糖及肾功能。

Objective To investigate the clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of diabetic nephropathy and its effect on urinary albumin excretion rate(UAER),vascular cell adhesion molecule-1(VCAM-1),collagen typeⅣ(CⅣ)and procollagen typeⅢ(PCⅢ).Methods Totally 70 patients with diabetic nephropathy admitted to our hospital from June 2016 to June 2017 were selected and divided into the experimental group and the control group according to the different treatment methods,35 cases in each group.The patients in the control group orally took 20 mg of Rosuvastatin Calcium Tablets,once a day,while the patients in the experimental group orally took 10 mg of Rosuvastatin Calcium Tablets combined with 10 mg of Ezetimibe Tablets,once a day.Both groups were continuously treated for 12 weeks.Results Compared with those before treatment,the levels of fasting blood glucose(FBG),serum creatinine(SCr),mean arterial pressure(MAP),blood urea nitrogen(BUN),UAER,VCAM-1,CⅣand PCⅢin the two groups were significantly decreased,and the improvement of the above indexes in the experimental group was significantly better than that in the control group(P<0.05).Conclusion Rosuvastatin combined with ezetimibe in the treatment of diabetic nephropathy can reduce the levels of UAER,VCAM-1,CⅣand PCⅢ,it also can improve blood glucose and renal function.